Webcasts
Strong Medicine: Strategies for Anti-Corruption Compliance in the Pharmaceutical Industry
January 25, 2012
1:00 PM ET | 10:00 AM PT
Registration: Only $59
Register Now
Featuring:
William P. Barry, , Partner, Richards Kibbe & Orbe LLP
Ed Silverman, Editor, Pharmalot, Editor-at-Large, Med Ad News
Register for this Webcast to understand:
The prosecution of global businesses under the Foreign Corrupt Practices Act (FCPA) is on the rise, with pharmaceutical and life sciences companies at the top of the DOJ’s list for investigations. Penalties in the hundreds of millions are no longer unusual. Under the FCPA companies can be liable for violations by agents, intermediaries and subsidiaries, as well as employees.
In this webinar, experienced enforcement and compliance attorney William Barry, of Richards Kibbe & Orbe LLP, will discuss how pharmaceutical companies can protect themselves and their employees from prosecution for FCPA violations. This presentation is tailored for compliance and legal professionals in the pharmaceutical industry, as well as marketing and operational personnel involved in cross-border business in the industry. Topics covered will include:
· FCPA Prohibited Payments
· Record Keeping and Accounting Controls Provision
· Internal Compliance Programs
· High Risk Areas in the Pharmaceutical Industry and FCPA Risk Mitigation Essentials
· Due Diligence on Third Parties/Transactions Including CROs and Other Agents
Wotta Story! How Biopharma Can Get, Manage — And Cope — With Media Coverage:
November 17, 2011
1:00 PM ET | 10:00 AM PT
Registration: Only $59
Register Now
Featuring:
Mike Huckman, Senior Vice President, Director of Media Strategy, MSLGROUP, Corporate/Healthcare, New York and former CNBC pharmaceuticals reporter
Ed Silverman, Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
You want your company to get noticed for all of the right reasons. So, why won’t the media pay attention? This is an opportunity for biopharma industry insiders to learn about how to increase the odds of your story getting told from a current journalist and blogger covering the sector and a former biotech reporter-turned-communications pro. Mike Huckman, SVP of PR-firm MSL New York and former CNBC pharmaceuticals reporter, and Pharmalot editor Ed Silverman will walk you through the ever-changing, challenging traditional media and social media landscape - and developing the right strategy to leverage it.
The Major Global Expansion of Rx-to-OTC Switch By 2016©:
OTC-ETM Drugs Will Lead the Way.
An Rx-to-OTC Switch Forecast and Guide
October 13, 2011
1:00 PM ET | 10:00 AM PT
Registration: Only $59
Register Now
Featuring:
Steven Francesco, CEO , Francesco International Inc, a late stage product lifecycle consulting firm and CEO, MMDerm LLC, a developer of innovative dermatology products. Also, formerly senior management at Schering-Plough, Sterling Drug, and Sandoz.
Ed Silverman, Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
There have been few Rx-to-OTC switches in recent years. However, that is about to change!
According to the recently released report by Francesco International Inc. the positive trend in Rx-to-OTC switches will be due to:
· Technology: The Game Changer Enabling Future Rx-to-OTC Switches Globally
· The New Enabled OTC-E™ Drugs: Therapeutic Sectors & Molecules
· Insurance / Reimbursement Changes: Expanded Treatment of Chronic Illness with OTCs
· Late Stage Product Lifecycle Management: Rx Portfolio Strategic and Operational Implications
· Lifecycle & Rx-to-OTC Switch Team Operations: Properly Setting Up and Managing Them
· Rx-to-OTC Switch Strategic and Operational Issues, Timelines and FDA Approval Process
· Future Rx-to-OTC Switch Approval: Challenges and Opportunities
Webcast: FDA Social Media Guidance: Fact or Fiction?
September 14, 2011
12:00 PM ET | 9:00 AM PT
View Webcast
Featuring:
Arnie Friede, , Friede & Associates, former FDA Associate Chief Counsel, and former Senior Corporate Counsel, Pfizer, I
Ed Silverman, Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
FDA has repeatedly promised, but failed to issue guidance on the distinct “rules” for using social media tools. At the same time, industry’s desire to exploit this medium constructively remains high. But what are the issues that FDA is grappling with in developing its long-awaited guidance? How, if at all, can industry usefully advance the ball by assisting FDA in the process? This webinar will identify and examine the four key issues that FDA must confront in promulgating guidance on social media:
(1) Disclosure
(2) Off-Label Promotion
(3) Accountability and Affiliation
(4) Adverse Event Reporting
We will disaggregate these issues, explain the legal, regulatory, and policy components of each, and offer suggestions for a constructive way forward for FDA. The webinar is a serious learning opportunity, presented by an expert in the field, for anyone interested in the evolution and implementation of rational FDA social media guidance.
How Can Pharma Use Social Media for Real-Time Intelligence and Research?
Tuesday, June 21, 2011
2pm ET | 11am PT
View Webcast
Featuring:
Adam Kleger, VP, Business Development, ListenLogic
Ed Silverman, Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
Social media discussions – especially within the healthcare arena – has grown exponentially over the past year. This phenomenal growth has been fueled by the rapid proliferation of interactive tools and online discussion spaces. For today’s pharmaceutical company, the immense volume of patient and caregiver conversations presents not only threats, but more importantly, opportunities for real-time action and long-term intelligence.
This webinar will review real world examples of how large corporations (both pharma and non-pharma) are leveraging social conversations across the enterprise. From R&D, to clinical trial recruitment, market research, corporate communications, marketing and sales, all the way up to c-level executives. We’ll also address the specific concerns of the highly regulated pharma industry, and discuss best practices of some of the innovators and pioneers.
Infusing Your Knowledge Of The Injectable Drug Delivery Market
Monday, May 23, 2011
2:00pm ET | 11:00AM PT
View Webcast
Featuring:
Katheryn Symank, Industry Analyst, Pharmaceutical & Biotechnology Healthcare North America, Frost & Sullivan
Ed Silverman, Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
The pharmaceutical and biotechnology industry is in a state of flux. Current challenges like patent expiration for a large amount of major name brand medications, increased production costs, increased generic presence, and declining new drug development necessitate new strategies that can better ensure future growth. An increasing amount of companies are focusing new drug development efforts towards high-interest specialty markets like cancer and technology areas such as biopharmaceuticals which offer new opportunities for growth and innovation.
Injectable medications are a significant part of the pharmaceuticals and biotechnology market and remain the most common drug delivery route for biopharmaceuticals and cancer drugs. Factors contributing to the development of injectable drugs are technological innovations for both injectables and devices and the high incidence of diseases that are treated with this delivery method.
Highlights of the briefing include: commentary on hot topics and trends associated with injectable drugs, analysis of NCE injectable pipeline compound distribution, primary research findings on MD and patient views of injectables, and CMO utilization trends for injectable drugs.
This briefing will benefit industry executives interested in injectable drugs and specialty pharmaceuticals including strategic planners, business development managers, research staff, marketing managers, as well as the investment and medical communities.
The Procurement Experience: A Panel of Experts Tells You How to Manage
Tuesday, April 26, 2011
1:00 PM ET | 10:00AM PT
View Webcast
Featuring:
Michael Thyen, Director, Marketing & Sales Global Procurement, Eli Lilly
Deborah Dick-Rath, Senior Vice President, Healthcare Practice Leader, FactorTG
Mark Schnurman, President/Co-Founder, Filament
Ed Silverman, Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
•How big a vote should procurement get in the decision making process?
•When should procurement get involved and what should their role be?
•What should procurement tell an agency before the pitch?
•Listen to our panelists discuss how they navigate the procurement process from both sides of the fence
Learn about Disclosing Physician Payments
Tuesday, March 15, 2011
1:00 PM ET | 10:00 AM PT
Duration: 1 hour
View Webcast
Featuring:
Sarah K. Giesting, Associate in the Health Care and Life Sciences Practice, EpsteinBeckerGreen
Ed Silverman Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
•Best ways to evaluate, develop and implement solutions toward transparency and aggregate spend
Gain understanding of the specific provisions of the law, including
•Timeline for reporting
•Key areas of reporting
•Key terms within the legislation
•Preemption between Federal and State laws
•Items excluded from federal reporting
•Penalties for failing to comply with the law
Don’t Miss the Overall: Pharmacovigilance, REMS and Risk Management
Monday, January 31, 2011
1:00 p.m. ET | 10:00 a.m. PT
Duration: 1 hour
View Webcast
Featuring:
Stephen A. Goldman, M.D., FAPM, DFAPA Managing Member, Stephen A. Goldman Consulting Services, L.L.C., Former Medical Director, MedWatch, US Food and Drug Administration
Ed Silverman Editor, Pharmalot, Editor-at-Large, Med Ad News and R&D Directions
Register for this Webcast to understand:
•Current national, regional and international perspectives and approaches to clinical trial safety
•Postmarketing pharmacovigilance and risk management
•The critical importance of the ICH “Pharmacovigilance Planning” E2E guideline in the current pharmaceutical safety environment
•Similarities and differences between EU-RMPs and FDAAA-mandated REMS